Unitaid is working with partners toward the global goal of ending HIV/AIDS as an epidemic by 2030.

We invest in innovations in medicine, diagnosis and prevention, and work with funders to introduce them on a large scale in low- and middle-income countries.

Nearly 38 million people were living with HIV in 2018, but 40% of them were not accessing treatment.

**OUR ACTIVE GRANT PORTFOLIO**

HIV/AIDS projects make up the largest segment of Unitaid’s US$ 1.3 billion grant portfolio.

**PREVENTION**

People at high risk of HIV can take PrEP, an oral prevention method, to protect themselves from getting infected. Unitaid is investing US$ 41 million in projects that feature PrEP. Partners include Fiotec in Brazil, Mexico and Peru, and Wits RHI in South Africa, working with the country’s Department of Health.

**TESTING AND MONITORING**

One in four people living with HIV do not know they have the virus. Our projects support quick, affordable, discreet tests that motivate more people to seek a diagnosis.

Unitaid has also invested US$150 million to improve technologies for testing viral load, the amount of virus present in the blood. A high viral load means a patient is taking their medicine incorrectly or needs a different treatment.

Among our projects:

- **US$ 97.4 MILLION**
  Unitaid is investing to create a market for HIV self-testing in Africa.

- **US$ 63 MILLION**
  Our project with Elizabeth Glaser Pediatric AIDS Foundation is bringing fast, point-of-care HIV testing to babies in Africa.

- **US$ 95 MILLION**
  Our collaboration with CHAI and UNICEF is expanding new technologies for early-infant diagnosis and viral load testing.
TREATMENT

**US$ 20 MILLION**
A 2019 Unitaid investment with CHAI supports measures to avert hundreds of thousands of preventable deaths among people with advanced HIV disease.

**US$ 17.3 MILLION**
To develop better HIV drugs for children in collaboration with Drugs for Neglected Diseases initiative (DNDi).

**US$ 67 MILLION**
Invested across four projects to bring the best HIV drugs to Africa, including treatments for pregnant women and people with tuberculosis.

**US$ 34 MILLION**
To widen access to the best-available HIV drugs, through a CHAI initiative.

**MILESTONES**
Unitaid’s HIV projects have slashed the price of antiretroviral drugs for children and second-line treatment for adults, and brought advanced point-of-care diagnostics to babies who live far from large health facilities.

The main contributors to Unitaid are: France, United Kingdom, Brazil, Norway, Chile, South Korea, Mauritius, Madagascar, Spain, and the Bill and Melinda Gates Foundation.

www.unitaid.org